Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 49, Issue 12, 2008, Pages 2328-2332

  Breccia, Massimo ^a   Stefanizzi, Caterina ^a   Cannella, Laura ^a   Latagliata, Roberto ^a   Frustaci, Anna Maria ^a   Carmosino, Ida ^a   Santopietro, Michelina ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic myeloid leukemia; Hematological; Imatinib; Non hematological toxicity

Indexed keywords

ANTIDIARRHEAL AGENT; DIURETIC AGENT; IMATINIB; INTERFERON; MAGNESIUM; STEROID;

ABDOMINAL PAIN; ARTICLE; BLADDER STONE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE PAIN; CANCER RESISTANCE; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CRYING; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; EYE DISEASE; FATIGUE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MUSCLE CRAMP; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PERIORBITAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SODIUM RESTRICTION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EXANTHEMA; HEMORRHAGE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MUSCLE CRAMP; NAUSEA; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 57449120869     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802578841     Document Type: Article

References (9)

1. Nowell, P. C. and Hungerford, D. A. (1960) A minute chromosome in human chronic granulocytic leukaemia. Science, 132, p. 1947.
2. Druker, B. J., Guilhot, F., O'Brien, S., Gathmann, I., Kantarjian, H. Gattermann, N. et al. (2006) Five years follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med, 355, pp. 2408-2417.
3. Breccia, M., Cannella, L., Frustaci, A., Stefanizzi, C., Levi, A. and Alimena, G. (2008) Cardiac events in imatinib mesylate-treated chronic myeloid leukaemia patients: A single institution experience. Leuk Res, 32, pp. 835-836.
4. Breccia, M., Gentilini, F., Cannella, L., Latagliata, R., Carmosino, I. Frustaci, A. et al. (2008) Ocular side effects in chronic myeloid leukaemia patients treated with imatinib. Leuk Res, 32, pp. 1022-1027.
5. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M. Cervantes, F. et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukaemia. N Engl J Med, 348, pp. 994-1004.
6. Deininger, M WN, O'Brien, S. G., Ford, J. M. and Druker, B. J. (2003) Practical management of patients with chronic myeloid leukaemia receiving imatinib. J Clin Oncol, 21, pp. 1637-1647.
7. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C. Gambacorti-Passerini, C. et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N Engl J Med, 346, pp. 645-652.
8. Sneed, T. B., Kantarjian, H., Talpaz, M., O'Brien, S. G., Rios, M. B. Bekele, B. N. et al. (2004) The significance of myelosuppresion during therapy with imatinib mesylate in patients with chronic myelogenous leukaemia in chronic phase. Cancer, 100, pp. 116-121.
9. Hochhaus, A., Druker, B., Sawyers, C., Guilhot, F., Schiffer, C. A. Cortes, J. et al. (2008) Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukaemia after failure of interferon-alpha treatment. Blood, 111, pp. 1039-1043.